• Norsk
  • English

June 2014

250 million NOK to Nordic Nanovector

Inven2s portfolio company Nordic Nanovector has attracted strong investor interest and has now raised 250 million NOK which will be used to fund further clinical development for treatment of non-Hodgkin Lymphoma.

Ansattrepresentant inn i Inven2s styre

Inven2s generalforsamling har besluttet å utvide styret med en ansattrepresentant. Helle Thorsen er valgt inn i styret som representant for de ansatte.